Supporting data for Mirabegron activates energy expenditure in human induced pluripotent stem cell (hiPSC)-derived beige adipocytes via a self-driven loop of the acetylcholine-acetylcholine receptor

 Modern people are exposed to an ever-increasing number of calories resulting in increasing obesity and related metabolic diseases. With the considerable developments in obese treatment, the differentiation ability of pluripotent embryonic stem (ES) cells makes it possible to be a potentially useful tool for disease modeling and therapeutic screening. Mirabegron is an FDA-approved drug to treat an overactive bladder by specifically activating the beta 3 adrenergic receptor. Recently it is found that people administered Mirabegron showed increased activity of thermogenic adipose tissue but the detailed mechanism is unclear. 

This dataset almost includes all the experiments in the project.  We generated human beige adipocytes from induced pluripotent stem cells (iPSCs), one kind of pluripotent cells with extended differentiation ability. The effects of mirabegron on EPSC-derived beige adipocytes were examined by Seahorse, glucose uptake studies. The cells were subjected to RNASeq and ATAC-Seq analysis. Glucose uptake was examined by 6-NBOG uptake and flow cytometry.